Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-02T20:02:00.179Z Has data issue: false hasContentIssue false
  • English
  • Français

A case in which mirtazapine reduced auditory hallucinations in a patient with Parkinson disease

Published online by Cambridge University Press:  30 November 2012

Tomoyuki Nagata ,
Shunichiro Shinagawa ,
Kenji Tagai  and
Kazuhiko Nakayama
Tomoyuki Nagata*
Affiliation:
Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan
Shunichiro Shinagawa
Affiliation:
Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan
Kenji Tagai
Affiliation:
Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan
Kazuhiko Nakayama
Affiliation:
Department of Psychiatry, Jikei University School of Medicine, Tokyo, Japan
*
Correspondence should be addressed to: Tomoyuki Nagata, Department of Psychiatry, Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. Phone: +81 334 331 111; Fax: +81 334 370 228. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

A 48-year-old woman with Parkinson disease (PD) suffered from auditory hallucinations (AH). We had treated her with a reduction in antiparkinsonian agents and the use of atypical antipsychotic agents. However, her symptoms did not improve, and her extrapyramidal symptoms (EPS) worsened. To lessen her depressive symptoms, treatment with a new-generation antidepressant, mirtazapine (MRZ), was commenced. The patient's AH gradually decreased with no worsening of EPS, and the AH disappeared 4 weeks after the commencement of treatment with MRZ. The present case suggests the effectiveness of MRZ for the treatment of refractory AHs in patients with PD.

Keywords

Parkinson disease (PD)psychosisantidepressants
Type
Case Report
Information
International Psychogeriatrics , Volume 25 , Issue 7 , July 2013 , pp. 1199 - 1201
Copyright
Copyright © International Psychogeriatric Association 2012 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Fénelon, G. (2008). Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectrums, 13, 18–25.CrossRefGoogle ScholarPubMed
Inzelberg, R., Kipervasser, S. and Korczyn, A. D. (1998). Auditory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry, 64, 533–535.CrossRefGoogle ScholarPubMed
Meco, G. and Bernardi, S. (2007). Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 31, 311–313.CrossRefGoogle ScholarPubMed
Normann, C.et al. (1997). Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine. Pharmacopsychiatry, 30, 263–265.CrossRefGoogle ScholarPubMed
Padala, K. P., Padala, P. R., Malloy, T. and Burke, W. J. (2010). New onset multimodal hallucinations associated with mirtazapine: a case report. International Psychogeriatrics, 22, 837–839.CrossRefGoogle ScholarPubMed
Ravina, B.et al. (2007). Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Movement Disorders, 22, 1061–1068.CrossRefGoogle ScholarPubMed
Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N. and Rochon, P. (2011) Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews.CrossRefGoogle Scholar
Tagai, K., Nagata, T., Shinagawa, S., Tsuno, N., Ozone, M. and Nakayama, K. (in press). Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics, 1–5, doi:10.1111/j.1479-8301.2012.00432.x.Google Scholar
Zahodne, L. B. and Fernandez, , , H. H. (2008). Pathophysiology and treatment of psychosis in Parkinson's disease: a review. Drugs and Aging, 25, 665–682.CrossRefGoogle ScholarPubMed
Zoldan, J., Friedberg, G., Livneh, M. and Melamed, E. (1995). Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology, 45, 1305–1308.CrossRefGoogle Scholar